Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults with treatment-resistant depression ...

Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with ...

Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression. The stock was down 22% to $31.62 in ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...

Supernus Pharmaceuticals beat analysts’ revenue ... Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its depression candidate SPN-820 failed to reach the main goals in a mid-stage ...

Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous ...

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...